Reston, VA—A new artificial intelligence tool provides a fully automated, easy-to-use and objective way to detect and evaluate brain tumors, according to new research published in the October issue of The Journal of Nuclear Medicine. Developed for use with amino acid PET scans, the deep learning-based segmentation algorithm can also assess brain tumor patients’ response to treatment with quality comparable to that of an experienced physician, but in a fraction of the time.
PET has become increasingly important in brain tumor diagnostics, complementing structural MRI. Over the past years, several studies have demonstrated the diagnostic value of the metabolic tumor volume for assessing treatment response in brain tumor patients. However, since measuring changes in the metabolic tumor volume of a brain tumor is time-consuming, it is usually not part of the routine clinical assessment.
“The fact that metabolic tumor volume is not routinely assessed in clinical practice suggests that the time and effort required for volumetric amino acid PET segmentation still exceeds clinical benefit,” said Philipp Lohmann, PhD, assistant professor (Habilitation) in Medical Physics, and team leader for Quantitative Image Analysis & AI at the Institute of Neuroscience and Medicine, Research Center in Juelich, Germany. “In response, our team developed a deep learning-based segmentation algorithm for a robust and fully automated volumetric evaluation of amino acid PET data and evaluated its performance for response assessment in patients with gliomas.”
Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576
Researchers retrospectively evaluated 699 18F-FET PET scans (at initial diagnosis or during follow-up) from 555 brain tumor patients. The deep learning-based segmentation algorithm was configured on a training and a test dataset, and changes in metabolic tumor volume were measured. Additionally, the algorithm was applied to data from a recently published 18F-FET PET study on response assessment in glioblastoma patients treated with adjuvant temozolomide chemotherapy. The response assessment from the algorithm was then compared to the assessment of an experienced physician, as reported in the study.
In the test dataset, 92 percent of lesions with increased uptake and 85 percent of lesions with isometric or hypometabolic uptake were correctly identified by the algorithm. Change in metabolic tumor volume, as detected by the algorithm, was a significant determinant of disease-free and overall survival, in agreement with the physician’s assessment.